Literature DB >> 28102094

Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in western cancer patients.

J J M Kwakman1, A Baars2, H Boot3, J F M Pruijt4, S B Winther5, P Pfeiffer5, C J A Punt1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28102094     DOI： 10.1080/0284186X.2016.1278459

Source DB:  PubMed          Journal:  Acta Oncol        ISSN： 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  4 in total

1.  Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.

Authors:  Stine Braendegaard Winther; Pia Österlund; Åke Berglund; Bengt Glimelius; Camilla Qvortrup; Halfdan Sorbye; Per Pfeiffer
Journal:  BMC Cancer       Date:  2017-08-16       Impact factor: 4.430

2.  Management of cytotoxic chemotherapy-induced hand-foot syndrome.

Authors:  Johannes J M Kwakman; Yannick S Elshot; Cornelis J A Punt; Miriam Koopman
Journal:  Oncol Rev       Date:  2020-05-13

3.  Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial.

Authors:  Ke Cheng; Yu-Wen Zhou; Ye Chen; Zhi-Ping Li; Meng Qiu; Ji-Yan Liu
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 3.302

4.  Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer.

Authors:  Se Jun Park; Hyunho Kim; Kabsoo Shin; Myung Ah Lee; Tae Ho Hong
Journal:  World J Gastrointest Oncol       Date:  2019-11-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.